SH2B3 P242S GERMLINE VARIANT ACTIVATES THE JAK2/STAT5 PATHWAY TO MEDIATE ABNORMAL ERYTHROCYTE PROLIFERATION

EHA Library, Yifan Duan, 4209940

AUTOIMMUNE PHENOTYPES AND MUTATIONAL PATTERNS IN MYELOID NEOPLASMS: AGE-DEPENDENT ASSOCIATIONS AND PROGNOSTIC IMPACT OF CLONAL HEMATOPOIESIS.

EHA Library, Sara Galimberti, 4209941

GENOME-WIDE CRISPR-CAS9 SCREENING IDENTIFIES NOVEL MEDIATORS OF RUXOLITINIB RESISTANCE IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Jian Huang, 4209942

ELUCIDATING THE IMPACTS OF TYROSINE KINASE INHIBITORS ON KIT SIGNALLING IN A SYSTEMIC MASTOCYTOSIS CELL LINE

EHA Library, Ben Weekes, 4209943

OPTICAL GENOME MAPPING IN TRIPLE-NEGATIVE ESSENTIAL THROMBOCYTHEMIA

EHA Library, Irene Botella Pérez, 4209944

EXOSOMAL MIR-146A, MIR-155 AND MIR-451A DYNAMICS DURING INTERFERON-ALPHA THERAPY IN PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Rodolfo Ortiz-Flores, 4209945

THE SOMATIC MUTATIONAL LANDSCAPE OF MYELOFIBROSIS WITH OR WITHOUT CYTOPENIA

EHA Library, Bing Han, 4209946

EXPOSURE TO AIR POLLUTANTS CORRELATES WITH AN INCREASED INCIDENCE OF MYELOPROLIFERATIVE NEOPLASMS: A POPULATION-BASED STUDY

EHA Library, Alessandro Bosi, 4209947

A MODERN THROMBOSIS RISK MODEL FOR MYELOPROLIFERATIVE NEOPLASMS: INTEGRATING INFLAMMATION, MOLECULAR MARKERS, AND SPLENIC BIOLOGY IN SINGLE CENTER REAL-WORLD COHORT.

EHA Library, Nouran Alhashimi, 4209948

JAK2 V617F ALLELE BURDEN MATTERS FOR RISK OF VENOUS THROMBOSIS AND OVERALL SURVIVAL IN ESSENTIAL THROMBOCYTHEMIA

EHA Library, Alberto Alvarez Larran, 4209949

EARLY AND LONGITUDINAL CHANGES IN LYMPHOCYTE SUBPOPULATIONS IN MYELOFIBROSIS PATIENTS TREATED WITH MOMELOTINIB

EHA Library, Novella Pugliese, 4209950

PLASMA PROTEOMIC SIGNATURES AT DIAGNOSIS IN MYELOPROLIFERATIVE NEOPLASMS FOR NOVEL DIAGNOSTIC BIOMARKERS

EHA Library, Xiangfu Zhong, 4209952

COEXISTENCE OF BCR::ABL1 AND JAK2 MUTATIONS IN MYELOPROLIFERATIVE NEOPLASMS: A CASE SERIES HIGHLIGHTING DUAL CLONAL HEMATOPOIESIS

EHA Library, Rene Amadore, 4209953

ALTERED LEVELS OF CYTOKINES INVOLVED IN FIBROCYTE DIFFERENTIATION IN PATIENTS WITH LYMPHOID MALIGNANCIES COMPLICATED BY SECONDARY MYELOFIBROSIS

EHA Library, Takaaki Maekawa, 4209954

PRIMARY MYELOFIBROSIS: FROM DISEASE PHENOTYPE AND AGE TO THE MOLECULAR ABERRATION PROFILE

EHA Library, Krzysztof Lewandowski, 4209955

IS THERE ANY RELATIONSHIP BETWEEN STROMAL MODIFICATIONS IN MYELOFIBROSIS AND THE MOLECULAR SIGNATURE OF THE HEMATOPOIETIC PROGENITOR?

EHA Library, Eduardo Rodríguez-Arbolí, 4209956

PREVALENCE OF THE JAK2 V617F MUTATION IN THE PERIPHERAL BLOOD OF INDIVIDUALS PRESENTING WITH ACUTE MYOCARDIAL INFARCTION

EHA Library, David Ross, 4209957

TPSAB1 COPY NUMBER ANALYSIS BY PLATE-BASED DIGITAL PCR IN HEREDITARY ALPHA TRYPTASEMIA (HΑT): A SINGLE-CENTER EXPERIENCE

EHA Library, Salvatore Piras, 4209958

DYNAMIC ROLES FOR ILC2S IN THE PATHOGENESIS OF BONE MARROW FIBROSIS

EHA Library, Maria Angeles Pinero Garasa, 4209959

EPIGENETIC LINEAGE TRACING OF CIRCULATING CELL-FREE DNA REVEALS DIFFERENTIAL CLONAL OUTPUT IN HEMATOLOGICAL MALIGNANCIES

EHA Library, Selin Toprak Yalçın, 4209960

MITOCHONDRIAL DNA DAMAGE CONTRIBUTES TO THE CYTOTOXIC EFFECT OF THE PEPTIDE–DRUG CONJUGATE MELFLUFEN

EHA Library, Ulrica WESTERMARK, 4209961

CO-OCCURRENCE OF DUAL DRIVER MUTATIONS IN MYELOPROLIFERATIVE NEOPLASMS: FREQUENCY AND PHENOTYPIC IMPLICATIONS IN AN ASIAN COHORT

EHA Library, Chih-Cheng Chen*, 4209962

STAGE-DEPENDENT IMMUNE PROFILING OF T AND NK CELLS IN MULTIPLE MYELOMA PATIENTS USING FLOW CYTOMETRY

EHA Library, Myung-Won Lee, 4209963

DEVELOPMENT AND VALIDATION OF A NOVEL PERIPHERAL BLOOD-BASED BIOMARKER PANEL FOR THE NON-INVASIVE DIAGNOSIS OF MULTIPLE MYELOMA AND PRECURSOR STATES

EHA Library, Irit Avivi Mazza, 4209964

REAL-WORLD TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH MYELOFIBROSIS TREATED FIRST-LINE WITH PACRITINIB OR RUXOLITINIB

EHA Library, James Rossetti, 4209965

LONG-TERM CLINICAL BENEFIT WITH AVAPRITINIB IN INDOLENT SYSTEMIC MASTOCYTOSIS: PIONEER LONG-TERM RESULTS WITH FOLLOW‑UP THROUGH 4 YEARS

EHA Library, Jens Panse, 4209966

THE COMBINATION OF RUXOLITINIB AND THE CDK4/6 INHIBITOR ABEMACICLIB DEMONSTRATES SAFETY AND EFFICACY IN PREVIOUSLY TREATED MYELOFIBROSIS PATIENTS: RESULTS OF A PHASE I STUDY

EHA Library, Raajit K Rampal, 4209967

FROM IMMUNOSUPPRESSION TO IMMUNE REBALANCING: EARLY IMMUNOLOGICAL EFFECTS OF MOMELOTINIB IN MYELOFIBROSIS

EHA Library, Andrea Duminuco, 4209968

UPDATED ANALYSIS OF OVERALL SURVIVAL (OS) WITH IMETELSTAT IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) FROM IMBARK VS REAL-WORLD (RW) DATA, AND ASSESSMENT OF RW TREATMENT PATTERNS

EHA Library, Andrew Kuykendall, 4209969

NEUTROPHIL EXTRACELLULAR TRAP FORMATION IS INCREASED IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS AND DECREASES WITH CYTOREDUCTIVE TREATMENT

EHA Library, Ingrid Lundahl, 4209970

COMPARATIVE PREDICTIVE PERFORMANCE OF QRISK3, SCORE2, AND PREVENT IN 568 PATIENTS WITH BCR::ABL1-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Alessandro Costa, 4209971

TRANSITORY NATURE OF SGLT-2 INHIBITOR ASSOCIATED ERYTHROCYTOSIS

EHA Library, Marko Lucijanic, 4209972

EFFECT OF TREATMENT WITH SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITORS AMONG PATIENTS ON OUTCOMES AMONG PATIENTS WITH POLYCYTHEMIA VERA AND TYPE 2 DIABETES MELLITUS

EHA Library, Gabriela Hobbs, 4209973

PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS AND ACQUIRED VON WILLEBRAND SYNDROME: ONLY PERTINENT AT DIAGNOSIS ?

EHA Library, Fanny Lemarié, 4209974

AGE-SPECIFIC RISK OF HEMATOLOGIC MALIGNANCIES AFTER ACUTE MYOCARDIAL INFARCTION: A NATIONWIDE COHORT STUDY

EHA Library, Kyoung Ha Kim, 4209975

AI-BASED SCORE VERSUS CONVENTIONAL PROGNOSTIC SCORES IN MYELOFIBROSIS: A SINGLE-CENTER VALIDATION STUDY

EHA Library, Marta Ricci, 4209976

BASELINE PREDICTORS OF SURVIVAL AND SPLEEN RESPONSE IN RUXOLITINIB-TREATED MYELOFIBROSIS: DEVELOPMENT OF THE R-PSS (RUXOLITINIB-PROGNOSTIC SCORING SYSTEM) IN A REAL-WORLD COHORT

EHA Library, Alessandro Laganà, 4209977

FATHERHOOD IN MYELOPROLIFERATIVE NEOPLASMS – A POPULATION BASED MATCHED COHORT STUDY OF 2 056 MEN

EHA Library, Anna Ravn Landtblom, 4209978

SYSTEMIC INFLAMMATION IMPROVES RISK PREDICTION IN MYELOFIBROSIS BEYOND DIPSS: DEVELOPMENT OF THE DIMOL SCORE

EHA Library, Amedeo Votto, 4209979

BASELINE CHARACTERISTICS BY PRE-SPECIFIED CYTOREDUCTIVE THERAPY IN HIGH-RISK POLYCYTHEMIA VERA IN THE PHASE III MITHRIDATE TRIAL WITH DESCRIPTIVE COMPARISON TO MAJIC-PV

EHA Library, Anastasia Kosmidou, 4209980

MUTATIONAL LANDSCAPE AND OUTCOME OF CALRETICULIN MUTATED MYELOFIBROSIS

EHA Library, Lucia Masarova, 4209981

RETROMOMELO: REAL-WORLD MOMELOTINIB USE AND OUTCOMES AFTER SWITCH BACK TO ANOTHER JAK INHIBITOR IN MYELOFIBROSIS - THE FRENCH EXPERIENCE FROM THE FIM GROUP

EHA Library, Mathilde Chanut, 4209982

EVALUATION OF GECACITINIB IN PATIENTS WITH  MYELOFIBROSIS：REAL-WORLD EVIDENCE FROM 52 CONSECUTIVE PATIENTS

EHA Library, Qiang Wang, 4209983

EUROPEAN REAL WORLD EVIDENCE STUDY OF JAK INHIBITOR COMBINATION WITH INTERFERON FOR MYELOPROLIFERATIVE NEOPLASMS - EXPLORING INDICATION, TOLERABILITY, RESPONSE AND OUTCOME.

EHA Library, Eric Lippert, 4209984

PATIENT-REPORTED OUTCOME MEASURES IN PATIENTS WITH POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA TREATED WITH RUXOLITINIB OR BEST AVAILABLE THERAPY IN THE RANDOMIZED PHASE 2B RUXOBEAT CLINICAL TRIAL

EHA Library, Steffen Koschmieder, 4209985

IMPACT OF RAPID VERSUS SLOW TITRATION OF ROPEGINTERFERON ALFA‑2B ON JAK2 V617F ALLELE BURDEN IN JAPANESE PATIENTS WITH POLYCYTHEMIA VERA

EHA Library, Toshiaki Sato, 4209986

INVOLVEMENT OF THE RESPIRATORY TRACT AND ITS DIAGNOSTIC AND THERAPEUTIC CONSEQUENCES IN PATIENTS WITH IDIOPATHIC HYPEREOSINOPHILIC SYNDROME

EHA Library, Vito Dangelo, 4209987

CLINICAL PHENOTYPE, GENETIC LANDSCAPE, AND OUTCOME IN PATIENTS WITH CO-OCCURRING MUTATIONS IN SF3B1 AND JAK2, CALR, OR MPL

EHA Library, Johannes Lübke, 4209988

OB756, A NOVEL SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS AND BASELINE THROMBOCYTOPENIA (<100×10⁹/L), ANEMIA (<100 G/L), AND MASSIVE SPLENOMEGALY: AN EXPLORATORY ANALYSIS

EHA Library, Jian Huang, 4209989

CLINICAL, GENOMIC, AND TREATMENT-RELATED OUTCOMES OF PATIENTS WITH HISTIOCYTIC SARCOMA TREATED BETWEEN 2000 TO 2025

EHA Library, Jenna Mahns, 4209990

EVALUATION OF THE FREQUENCY, RISK FACTORS, AND OUTCOMES OF SPLANCHNIC VEIN THROMBOSIS IN MYELOPROLIFERATIVE NEOPLASMS: A RETROSPECTIVE COHORT STUDY

EHA Library, Ufuk Demirci, 4209991

LONGITUDINAL GENOMIC SHIFTS ASSOCIATED WITH DISEASE TRANSFORMATION IN PATIENTS WITH POLYCYTHEMIA VERA (PV) ENROLLED IN REVEAL

EHA Library, Stephen Oh, 4209992

GECACITINIB TENDS TO RESTORE IMMUNE FUNCTION IN RUXOLITINIB EXPOSED MYELOFIBROSIS PATIENTS

EHA Library, Yunfan Yang, 4209993

TREATMENT STRATEGY AND THROMBOTIC STATUS SHAPE BLEEDING RISK IN 15,495 PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Stefanie Antonilli, 4209995

PREDICTORS OF ANEMIA RESPONSE TO MOMELOTINIB IN MYELOFIBROSIS: EVIDENCE FROM A LARGE REAL-WORLD COHORT

EHA Library, Lucía Pérez Lamas, 4209996

PROGNOSTIC ROLE OF INFLAMMATION IN MPN:EVALUATING NLR, RAR, AND COMORBIDITY BURDEN

EHA Library, Isidora ARSENOVIC, 4209997

ANEMIA RECOVERY IDENTIFIES PROGNOSTIC HETEROGENEITY IN CYTOPENIC MYELOFIBROSIS: A POPULATION BASED REAL-WORLD ANALYSIS

EHA Library, Regina García Delgado, 4209998

ESTIMATED PREVALENCE OF POLYCYTHEMIA VERA IN EUROPE: 2025-2030

EHA Library, Haifa Kathrin Al-Ali, 4209999

CLINICAL CHARACTERISTICS AND PROGNOSTIC ANALYSIS FOR OTHER MALIGNANCIES AMONG PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Xiaojing Wei, 4210000

LONG TERM LOW RISK PEDIATRIC LANGERHANS CELL HISTIOCYTOSIS (LCH).  DOES CENTRAL NERVOUS SYSTEM CNS + RISK SITE BONES AFFECT THE OUTCOME? A 15-YEAR OF EXPERIENCE.

EHA Library, Mohamed Sedky, 4210001

ICC/WHO-DEFINED AND NGS-ANNOTATED IDIOPATHIC HYPEREOSINOPHILIA: MUTATIONS, CLINICAL AND TREATMENT DETAILS, AND PREDICTORS OF SURVIVAL

EHA Library, Shraddha Patel, 4210002

PATHOLOGIC FRACTURES INDEPENDENTLY INCREASE MORTALITY AND HEALTHCARE UTILIZATION IN HOSPITALIZED PATIENTS WITH MULTIPLE MYELOMA: A CONTEMPORARY NATIONAL ANALYSIS

EHA Library, Lydia Francis, 4210003

LONG-TERM FOLLOW-UP OUTCOMES AND RISK FACTORS FOR DISEASE PROGRESSION IN 2064 PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA: A REAL-WORLD MULTICENTER STUDY FROM ZHEJIANG PROVINCE, CHINA

EHA Library, Jian Huang, 4210004

REAL-WORLD HEMATOLOGIC OUTCOMES WITH MOMELOTINIB IN PATIENTS WITH MYELOFIBROSIS AND ANEMIA: A GERMAN RETROSPECTIVE CHART REVIEW

EHA Library, Haifa Kathrin Al-Ali, 4210005

LOW-DOSE HYPOMETHYLATING AGENTS IN THE TREATMENT OF CYTOPENIC CHRONIC MYELOPROLIFERATIVE NEOPLASMS: A RETROSPECTIVE ANALYSIS FROM A SINGLE CENTER

EHA Library, Tingting Cui, 4210006

NEUTROPHIL-TO-LYMPHOCYTE (NLR) AND PLATELET-TO-LYMPHOCYTE RATIOS (PLR) DO NOT CORRELATE WITH SYMPTOM BURDEN IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Ivan Krecak, 4210007

CLINICAL CHARACTERISTICS, TREATMENT OUTCOMES, AND GENETIC PROFILING OF LANGERHANS CELL HISTIOCYTOSIS: A SINGLE-CENTER RETROSPECTIVE STUDY OF 202 PEDIATRIC PATIENTS

EHA Library, QIHONG LIN, 4210008

BCR::ABL1 NEGATIVE MYELOPROLIFERATIVE NEOPLASMS REPRESENT A DISTINCT ENTITY IN THE PAEDIATRIC AND YOUNG ADULT POPULATION – A MULTI-CENTRE RETROSPECTIVE STUDY

EHA Library, Abbie Wilson, 4210009

UNDERSTANDING DISEASE BURDEN AND LIVED EXPERIENCES IN PATIENTS WITH POLYCYTHAEMIA VERA BY CONDUCTING A REAL-WORLD SOCIAL MEDIA LISTENING STUDY ACROSS EUROPE

EHA Library, Alesia Khan, 4210010

THROMBOTIC RISK AND PREDICTORS OF PROGRESSION TO OVERT MYELOFIBROSIS IN PRE-FIBROTIC MYELOFIBROSIS: A MULTICENTER PROSPECTIVE COHORT STUDY

EHA Library, Novella Pugliese, 4210011

HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH MYELOFIBROSIS: A CHINESE MULTICENTER RETROSPECTIVE STUDY

EHA Library, Yuqian Sun, 4210012

ROPEGINTERFERON ALFA-2B IS EFFECTIVE AND SAFE IN ESSENTIAL THROMBOCYTHEMIA PATIENTS LACKING CYTOREDUCTIVE TREATMENT OPTIONS INDEPENDENT OF TREATMENT HISTORY AND RISK GROUP

EHA Library, Francesca Palandri, 4210013

SEX INFLUENCES PROGNOSIS OF ADOLESCENTS AND YOUNG ADULTS WITH CLASSICAL BCR::ABL1 NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Yanan Cai, 4210014

SOCIOECONOMIC DEPRIVATION IS ASSOCIATED WITH INCREASED MORTALITY RISK AMONG PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Nauman Butt, 4210015

DYNAMIC CHANGES IN BONE MARROW FIBROSIS DURING TREATMENT INDEPENDENTLY PREDICT OUTCOMES IN MPN-ASSOCIATED MYELOFIBROSIS

EHA Library, Yunfan Yang, 4210016

EVALUATING THROMBOTIC RISK AND HEMATOCRIT EFFECT OF INTRAVENOUS IRON REPLETION IN CYTOREDUCED PATIENTS WITH POLYCYTHEMIA VERA

EHA Library, Katherine Feder, 4210017

THE DISCRIMINATIVE VALUE OF FLOW CYTOMETRY-BASED ANALYSIS OF CIRCULATING MYELOBLASTS IN ESSENTIAL THROMBOCYTHEMIA AND PRIMARY MYELOFIBROSIS

EHA Library, Gréta Garami, 4210018

STUDY ON VASCULAR ENDOTHELIAL FUNCTION IN PATIENTS WITH POLYCYTHEMIA VERA: A SINGLE-CENTER ANALYSIS

EHA Library, Weronika Lebowa, 4210019

BELOW THE THRESHOLD, ABOVE THE RISK: THROMBOTIC IMPLICATIONS OF JAK2 VAF

EHA Library, Laura De Fazio, 4210020

IMMATURE PLATELET FRACTION REFLECTS DYSREGULATED THROMBOPOIESIS IN PHILADELPHIA-NEGATIVE MPNS

EHA Library, Ivan Zekanovic, 4210021

SYMPTOMATIC HIP AND KNEE OSTEOARTHRITIS IS ASSOCIATED WITH HIGHER SYMPTOM BURDEN AND HIGHER THROMBOTIC RISK IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Hrvoje Holik, 4210022

ASSOCIATION OF CLINICAL AND MOLECULAR RISK FACTORS WITH SEVERITY OF ANEMIA ASSOCIATED WITH MYELOFIBROSIS

EHA Library, Verna Cheung, 4210023

REAL WORLD PRACTICE REVEALS HEMATOLOGIC INDICES AS EFFICACY PREDICTORS FOR MYELOFIBROSIS PATIENTS SWITCHING FROM RUXOLITINIB TO GECACITINIB

EHA Library, Xinjie Chen, 4210024

COMPARISON OF ROTEM IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS AND CONTROLS WITH NON-CLONAL POLYCYTHEMIA AND/OR THROMBOLEUKOCYTOSIS AND FOLLOWING INITIATION OF CYTOREDUCTION

EHA Library, Alsu Gatina, 4210025

BEYOND SIX MONTHS: EXTENDED REAL-WORLD VALIDATION OF THE RR6 MODEL FOR EARLY RISK STRATIFICATION IN RUXOLITINIB-TREATED MYELOFIBROSIS

EHA Library, Erika Morsia, 4210027

DYNAMIC DNA METHYLATION CHANGES DURING DISEASE COURSE IN JUVENILE MYELOMONOCYTIC LEUKEMIA

EHA Library, chenmeng Liu, 4210028

A PHASE 1 MULTICENTER STUDY OF INCB160058, A JAK2V617F MUTANT–SELECTIVE INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS, POLYCYTHEMIA VERA, OR ESSENTIAL THROMBOCYTHEMIA: STUDY DESIGN AND RATIONALE

EHA Library, Jason Gotlib, 4210029

A REAL-WORLD STUDY OF GECACITINIB IN THE TREATMENT OF MYELOFIBROSIS FROM CHINA: A SINGLE-CENTER RETROSPECTIVE STUDY

EHA Library, Jin Mao, 4210030

REAL-WORLD HEMOGLOBIN MODULATION PATTERNS WITH GECACITINIB IN MYELOFIBROSIS: IMPACT OF BASELINE ANEMIA SEVERITY

EHA Library, Jian Huang, 4210031

TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH THE KIT INHIBITOR AVAPRITINIB: A RIMA (RETE ITALIANA MASTOCITOSI) REAL-LIFE DATASET COLLECTION

EHA Library, Chiara Elena, 4210032

INCIDENCE AND PREVALENCE OF MYELOPROLIFERATIVE NEOPLASMS – A POPULATION-BASED STUDY FROM SWEDEN

EHA Library, Anna Ravn Landtblom, 4210033

CLONAL HEMATOPOIESIS IS A ROBUST PREDICTOR OF RESPONSE TO INTERFERON-Α IN ERDHEIM-CHESTER DISEASE AND MYELOPROLIFERATIVE NEOPLASMS.

EHA Library, Jerome Razanamahery, 4210034

A DEEP SAMPLING AND SINGLE MOLECULE DIGITAL COUNTING ASSAY FOR RARE MOLECULE DETECTION

EHA Library, Eleen Shum, 4210035

INTESTINAL INFLAMMATION IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Ivan Krecak, 4210036

COMPARATIVE VALUE OF NOVEL DIPSS-R VERSUS DIPSS BASED PROGNOSTICATION IN PATIENTS WITH MYELOFIBROSIS

EHA Library, Marko Lucijanic, 4210037

REAL-WORLD APPLICATION OF 2024 IWG-ELN CRITERIA FOR ANEMIA RESPONSE IN MOMELOTINIB-TREATED MYELOFIBROSIS

EHA Library, Francesca Duca, 4210038

EPIDEMIOLOGY, TREATMENT PATTERNS AND OUTCOMES IN MYELOFIBROSIS IN GERMANY: A HEALTH CLAIMS-BASED ANALYSIS

EHA Library, Haifa Kathrin Al-Ali, 4210039

FOXP1 MUTATIONS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS TRANSFORMING TO MYELOFIBROSIS

EHA Library, Bruno Cassinat, 4210040

IMPACT OF ADDITIONAL MUTATIONS ON FIRST-LINE TREATMENT RESPONSE AND DISEASE PROGRESSION IN ESSENTIAL THROMBOCYTHEMIA

EHA Library, Novella Pugliese, 4210041

SHEAR-WAVE ELASTOGRAPHY IDENTIFIES A DYNAMIC SURROGATE IMAGING ENDPOINT OF MOMELOTINIB ACTIVITY IN A REAL-WORLD MYELOFIBROSIS COHORT

EHA Library, Amedeo Votto, 4210042